Athersys Inc. (ATHX)

2.06
0.03 1.40
NASDAQ : Health Technology
Prev Close 2.09
Open 2.11
Day Low/High 2.00 / 2.15
52 Wk Low/High 1.29 / 2.63
Volume 734.96K
Avg Volume 598.60K
Exchange NASDAQ
Shares Outstanding 125.83M
Market Cap 262.98M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Athersys CEO To Speak At The 2018 Brain Health Summit

Athersys CEO To Speak At The 2018 Brain Health Summit

Event held in conjunction with Super Bowl LII will focus on key issues in neurological medicine and women's brain health

HEALIOS Announces Enrollment Of First Patient In Japan In TREASURE Study Of MultiStem® Treatment For Ischemic Stroke

HEALIOS Announces Enrollment Of First Patient In Japan In TREASURE Study Of MultiStem® Treatment For Ischemic Stroke

Off-the-shelf stem cell therapy has potential to extend treatment window and enhance recovery for stroke patients

Athersys Reports Third Quarter 2017 Results

Athersys Reports Third Quarter 2017 Results

Management to host conference call at 4:30 pm EST today

Athersys And Nikon CeLL Innovation To Collaborate On MultiStem® Commercial Manufacturing In Japan

Athersys And Nikon CeLL Innovation To Collaborate On MultiStem® Commercial Manufacturing In Japan

Technology transfer of stem cell production methods in preparation for potential commercialization in Japan following TREASURE clinical study

Athersys Reports Second Quarter 2017 Results

Athersys Reports Second Quarter 2017 Results

Management to host conference call at 4:30pm EDT today

First Week of January 2018 Options Trading For Athersys (ATHX)

Investors in Athersys Inc saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Short Interest Makes 21% Move For ATHX

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 866,866 share increase in total short interest for Athersys Inc , to 4,997,005, an increase of 20.99% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Two New Publications Highlight The Potential For MultiStem® Treatment Of Ischemic Stroke

Lancet Neurology/Stem Cells publications provide further clarity of MultiStem mechanisms of benefit - modulating inflammatory response and immune system - enhancing recovery

Overview Of MultiStem® Clinical Trial In Japan Presentation At International Stroke Conference 2017

Details of Healios' Phase II/III trial (HLCM051) being presented by stroke expert and lead investigator Dr. Kyohiro Houkin

Athersys Reports Third Quarter 2016 Results

Athersys Reports Third Quarter 2016 Results

Management to host conference call at 4:30 pm EST today

TheStreet Quant Rating: D- (Sell)